In a significant breakthrough, a randomized, double-blind, placebo-controlled trial conducted at a tertiary referral center in Hong Kong reveals the potential efficacy of synbiotic preparation SIM01 in alleviating symptoms of Post-Acute COVID-19 Syndrome (PACS). The study, involving 463 patients with confirmed SARS-CoV-2 infection, showed that those receiving SIM01 for six months exhibited notably higher rates of symptom alleviation, particularly in fatigue, memory loss, difficulty in concentration, gastrointestinal upset, and general unwellness, compared to the placebo group. Noteworthy predictors of symptom alleviation included SIM01 treatment, infection with omicron variants, prior COVID-19 vaccination, and experiencing mild acute COVID-19. Adverse event rates were similar between the two groups, highlighting the safety of the synbiotic therapy. These findings underscore the potential of gut microbiome modulation through SIM01 in managing PACS. This breakthrough offers hope for the millions worldwide grappling with persistent COVID-19 symptoms, suggesting a promising avenue for enhancing recovery and addressing the post-acute phase of the virus.
Source: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00685-0/fulltext
